

**Ambee Pharmaceuticals Limited**  
**3rd Quarter Accounts(Un-Audited)**  
**January to March-2017**

**Ambee Pharmaceuticals Limited**  
**Statement of Financial Position (Un-audited)**  
**As at 31st March 2017**

Taka '000

|  | <i>31st Mar 2017</i> | <i>30 June.2016</i> |
|--|----------------------|---------------------|
| <b>ASSETS</b>  |                      |                     |
| <b>Non-Current Assets:</b>                               | 94,024               | 95,183              |
| Property, Plant & Equipment -Carrying Value              | 94,024               | 95,183              |
| <b>Current Assets:</b>                                   | 328,602              | 326,970             |
| Inventories  | 164,830              | 165,208             |
| Trade Receivable   | 72,120               | 70,989              |
| Advances, Deposits and Pre-payments                      | 79,021               | 78,111              |
| Short Term Investment                                    | -                    | -                   |
| Cash and Cash Equivalents                                | 12,631               | 12,662              |
| <b>Total Assets</b>                                      | <b>422,626</b>       | <b>422,153</b>      |
| <b>EQUITY AND LIABILITIES</b>                            |                      |                     |
| <b>Capital and Reserves:</b>                             | 58,896               | 59,564              |
| Share Capital  | 24,000               | 24,000              |
| Tax-Holiday Reserve                                      | 5,134                | 5,134               |
| Retained Earnings- As per statement of changes in equity | 29,762               | 30,430              |
| <b>Non-Current Liabilities:</b>                          | 7,063                | 7,149               |
| Deferred Tax Liabilities                                 | 7,063                | 7,149               |
| <b>Current Liabilities and Provisions:</b>               | 356,667              | 355,440             |
| Short Term Credit Facility                               | 197,021              | 198,368             |
| Creditors and Other Payables                             | 159,646              | 157,072             |
| <b>Total Equity And Liabilities</b>                      | <b>422,626</b>       | <b>422,153</b>      |
| <b>Net Asset Value per share (NAV)</b>                   | <b>24.54</b>         | <b>24.82</b>        |



(Aziz Mohammad Bhai)  
Chairman



(Naureen Aziz Mohammad Bhai)  
Managing Director



(Nurjehan Huda)  
Director



(A.K.M. Khairul Aziz)  
Chief Financial Officer

For   
Company Secretary

Dhaka  
26 April, 2017

## Ambee Pharmaceuticals Limited

### Statement of Comprehensive Income For the 3rd Quarter ended 31st March 2017 (Unaudited)

|   | <i>9 Month Ended</i><br><i>July 16-March 17</i> | <i>9 Month Ended</i><br><i>July 15-March 16</i> | <i>3rd Quarter Ended</i><br><i>Jan-March.17</i> | <i>Taka '000</i><br><i>3rd Quarter Ended</i><br><i>Jan-March.16</i> |
|---|---|---|---|---|
| <b>Revenue (Turnover) from Net Sales</b>  | <b>274,071</b>                                  | <b>263,827</b>                                  | <b>96,015</b>                                   | <b>81,895</b>   |
| Cost of Goods Sold                        | (128,835)                                       | (123,506)                                       | (41,325)  | (35,123)  |
| <b>Gross Profit</b>                       | <b>145,236</b>                                  | <b>140,321</b>                                  | <b>54,690</b>                                   | <b>46,772</b>   |
| <b>Operating Expenses :</b>               | <b>(124,803)</b>                                | <b>(116,980)</b>                                | <b>(47,032)</b>                                 | <b>(38,986)</b>   |
| Administrative Expenses                   | (16,635)  | (15,994)  | (4,248)   | (3,498)   |
| Marketing and Selling Expenses            | (108,168)                                       | (100,986)                                       | (42,784)  | (35,488)  |
| <b>Profit for Operation</b>               | <b>20,433</b>                                   | <b>23,341</b>                                   | <b>7,658</b>                                    | <b>7,786</b>  |
| Non Operating Income                      |   | 489   | -   | -   |
| Financial Expenses                        | (12,604)  | (15,674)  | (4,696)   | (6,019)   |
| <b>Profit Before Contribution to WPPF</b> | <b>7,829</b>                                    | <b>8,156</b>                                    | <b>2,962</b>                                    | <b>1,767</b>  |
| Contribution to WPPF                      | (391)   | (393)   | (148)   | (88)  |
| <b>Net Profit before income-tax</b>       | <b>7,438</b>                                    | <b>7,763</b>                                    | <b>2,814</b>                                    | <b>1,679</b>  |
| <b>Provision for income -tax</b>          | <b>(1,865)</b>                                  | <b>(1,622)</b>                                  | <b>(603)</b>                                    | <b>(315)</b>  |
| Current Tax                               | (1,822)   | (1,889)   | (689)   | (420)   |
| Deferred Tax Income/ (Expenses)           | (43)  | 267   | 86  | 105   |
| <b>Net Profit after income-tax</b>        | <b>5,572</b>                                    | <b>6,141</b>                                    | <b>2,210</b>                                    | <b>1,364</b>  |
| <b>Number of Shares</b>                   | <b>2,400</b>                                    | <b>2,400</b>                                    | <b>2,400</b>                                    | <b>2,400</b>  |
| <b>Earnings Per Share (EPS)</b>           | <b>2.32</b>                                     | <b>2.56</b>                                     | <b>0.92</b>                                     | <b>0.57</b>   |



(Aziz Mohammad Bhai)  
Chairman



(Naureen Aziz Mohammad Bhai)  
Managing Director



(Nurjehan Hudda)  
Director



(A.K.M. Khairul Aziz)  
Chief Financial Officer

For   
Company Secretary

Dhaka  
26, April, 2017

**Ambee Pharmaceuticals Limited**  
**Statement of Cash Flows (Un-audited)**  
***For the period from 1st July 2016 to 31st March 2017***

*Taka '000*

|   | <i>3rd Quarter Ended<br/>July'16-March'17</i> | <i>3rd Quarter Ended<br/>July'15-March'16</i> |
|---|---|---|
| <b>Cash Flows from Operating Activities :</b>     |   |   |
| Collection from turnover                          | 272,940                                       | 265,288                                       |
| Payments for cost and expenses                    | (238,188)                                     | (233,111)                                     |
| Finance Expenses                                  | (12,604)                                      | (15,674)                                      |
| Income-tax paid/deducted at source                | (2,150)                                       | (2,356)                                       |
| <b>Cash Generated from Operating Activities :</b> | <b>19,998</b>                                 | <b>14,147</b>                                 |
| <b>Cash Flows from Investing Activities :</b>     |   |   |
| Acquisition of Fixed Assets                       | (792)   | (1,059)                                       |
| <b>Cash Generated From Investment Activities</b>  | <b>(792)</b>                                  | <b>(1,059)</b>                                |
| <b>Cash Flows from Financing Activities :</b>     |   |   |
| Other Finance                                     | (5,288)                                       | (6,358)                                       |
| Dividend Paid                                     | (13,949)                                      | (10,212)                                      |
| <b>Cash Generated From Financial Activities</b>   | <b>(19,237)</b>                               | <b>(16,570)</b>                               |
| Increase/(Decrease) in cash and cash equivalents  | (31)  | (3,482)                                       |
| Opening cash and cash equivalents                 | 12,662  | 26,576  |
| Closing Cash and Bank balances                    | <u><u>12,631</u></u>                          | <u><u>23,094</u></u>                          |
| <b>Net Operating cash flow per share</b>          | <u><u>8.33</u></u>                            | <u><u>5.89</u></u>                            |
| <b>Components of Cash and Cash Equivalents</b>    |   |   |
| Cash and Cash Equivalents                         | 12,631  | 12,527  |
| Short Term Investment                             | -   | 10,567  |
| Total Cash and Cash Equivalents                   | <u><u>12,631</u></u>                          | <u><u>23,094</u></u>                          |



(Aziz Mohammad Bhai)  
Chairman



(Naureen Aziz Mohammad Bhai)  
Managing Director



(Nurjehan Hudda)  
Director



(A.K.M. Khairul Aziz)  
Chief Financial Officer

For   
Company Secretary

# **Ambee Pharmaceuticals Limited**

## **Statement of Changes in Equity**

**For the 3rd quarter ended 31st March, 2017**

**(Unaudited)**

**As at 31st March,2017**


***Taka '000***

|   | <b>Share<br/>Capital</b> | <b>Tax Holiday<br/>Reserve</b> | <b>Retained<br/>Earning</b> | <b>Total</b>  |
|---|--------------------------|--------------------------------|-----------------------------|---------------|
| At 1st July 2016                                    | 24,000                   | 5,134                          | 30,430                      | 59,564        |
| Dividend Paid for the year 2016                     |                          |                                | (6,240)                     | (6,240)       |
| Net Profit after income-tax July 2016 to March 2017 |                          |                                | 5,572                       | 5,572         |
| <b>At 31st March 2017</b>                           | <b>24,000</b>            | <b>5,134</b>                   | <b>29,762</b>               | <b>58,896</b> |
| <b>At 30th June 2016</b>                            | <b>24,000</b>            | <b>5,134</b>                   | <b>30,430</b>               | <b>59,564</b> |

**As at March,2016**

***Taka '000***

|   | <b>Share<br/>Capital</b> | <b>Tax Holiday<br/>Reserve</b> | <b>Retained<br/>Earning</b> | <b>Total</b>  |
|---|--------------------------|--------------------------------|-----------------------------|---------------|
| At 1st July 2015                                    | 24,000                   | 5,134                          | 33,097                      | 62,231        |
| Dividend Paid for the year 2014                     |                          |                                | (6,720)                     | (6,720)       |
| Net Profit after income-tax July 2015 to March 2016 |                          |                                | 6,141                       | 6,141         |
| <b>At 31st March 2016</b>                           | <b>24,000</b>            | <b>5,134</b>                   | <b>32,518</b>               | <b>61,652</b> |
| <b>At 30th June 2015</b>                            | <b>24,000</b>            | <b>5,134</b>                   | <b>33,097</b>               | <b>62,231</b> |



(Aziz Mohammad Bhai)  
Chairman



(Naureen Aziz Mohammad Bhai)  
Managing Director



(Nurjehan Hudda)  
Director



(A.K.M. Khairul Aziz)  
Chief Financial Officer

For



Company Secretary

Dhaka  
26 April, 2017